À retenir
In a placebo-controlled trial of 120 adults aged 30-59 with persistent fatigue, 6 g/day of L-arginine lowered Fatigue Severity Scale scores more than placebo at 8 weeks (-6.41 vs. -2.23; Holm-adjusted p = 0.024), while 3 g/day did not. Mean scores stayed above the enrollment threshold, so fatigue was reduced, not resolved.
Study design
Essai randomisé
Reading basis
Published abstract
Reading focus
Comparator & uncertainty
Cette explication éditoriale existe en anglais, chinois simplifié et chinois traditionnel. Cette interface affiche la lecture en anglais.
Question de recherche
Many working adults feel tired every day, and the evidence for nutritional treatments is limited. The authors tested whether the amino acid L-arginine reduces persistent fatigue, and also looked at sleep and how the blood clears lactate after a treadmill run.
Population et méthode
Randomized, double-blind, placebo-controlled trial of 8 weeks in 120 community-dwelling adults aged 30-59 years with persistent fatigue (Fatigue Severity Scale [FSS] total of 27 or more), given oral L-arginine 3 g/day, 6 g/day or placebo. The primary endpoint was FSS change. Secondary endpoints included the Checklist Individual Strength (CIS), the Pittsburgh Sleep Quality Index (PSQI) and blood lactate during a standardized 30-minute submaximal treadmill run at about 70% VO2max. Data from 119 participants were analyzed with Holm adjustment for multiple comparisons.
Résultats
The authors’ reported results. Read each estimate with its population and uncertainty.
- 1At week 8, FSS fell more with 6 g/day than placebo (-6.41 vs. -2.23; Holm-adjusted p = 0.024). The 3 g/day dose did not differ from placebo.
- 2The CIS improvement with 6 g/day did not survive adjustment for multiple comparisons.
- 3PSQI sleep scores improved nominally with both doses (3 g/day, p = 0.007; 6 g/day, p = 0.045), the abstract not stating adjusted values for these.
- 4With 6 g/day, total lactate area under the curve (Holm-adjusted p = 0.041) and lactate at 15 minutes of recovery (Holm-adjusted p = 0.002) were lower than with placebo; resting plasma nitrite did not differ. No serious adverse events occurred.
Limites et incertitude
- 1Only 120 adults were enrolled over 8 weeks, so this cannot show longer-term benefit or safety.
- 2Fatigue was measured with self-rated scales, which can respond to expectation even in a placebo-controlled trial, and mean FSS scores remained above the entry threshold.
- 3The sleep (PSQI) improvements are nominal rather than corrected for multiple comparisons, and the 3 g/day dose showed no fatigue effect, so the dose pattern is not clean.
- 4The abstract does not give the funder or confidence intervals; this reading is based on the abstract only.
Mise en perspective
L-arginine at 6 g/day gave a modest reduction in everyday fatigue over 8 weeks in this trial, not a cure. One trial is not enough to recommend it. Persistent fatigue can have medical causes, and supplements should be discussed with a clinician or pharmacist first.
Vos données
If you track sleep and training, note any change in how a standard workout feels and in your sleep duration alongside a weekly fatigue rating on the same scale. Heart rate at a fixed easy pace and recovery heart rate from the same device are more reliable to compare than single sessions. Blood lactate from this trial cannot be measured by a wearable.
Comprendre ce type de preuve
Randomisation can support causal inference, but check allocation, blinding, missing outcomes, follow-up and the actual comparator. A trial label alone does not establish high certainty.
Résumé structuré des auteurs English
Le résumé original en anglais est reproduit avec attribution sous la licence ouverte indiquée. Il s’agit d’une source, pas d’une interprétation MoveVitals. L’analyse préparée figure ci-dessus ; vérifiez les conclusions importantes dans la source.
Background/objectives
The evidence for nutritional interventions against fatigue is limited; we evaluated whether L-arginine reduces fatigue in working-age adults.
Methods
In this 8-week randomized, double-blind, placebo-controlled trial, 120 community-dwelling working-age adults aged 30-59 years with persistent fatigue (Fatigue Severity Scale [FSS] total ≥ 27) received oral L-arginine 3 g/day, 6 g/day, or placebo. The primary endpoint was FSS change; secondary endpoints included the Checklist Individual Strength (CIS), Pittsburgh Sleep Quality Index (PSQI), and blood lactate kinetics during a standardized submaximal treadmill run (~70% VO_(2)max, 30 min). Data from 119 participants were analyzed, with Holm adjustment for multiplicity.
Results
At Week 8, FSS decreased more with 6 g/day than with placebo (-6.41 vs. -2.23; Holm-adjusted p = 0.024), whereas 3 g/day did not differ from placebo. The 6 g/day CIS improvement did not survive multiplicity adjustment. PSQI scores improved nominally at both doses (3 g/day, p = 0.007; 6 g/day, p = 0.045). With 6 g/day, the total lactate area under the curve (Holm-adjusted p = 0.041) and 15-min recovery lactate (Holm-adjusted p = 0.002) were lower than with the placebo, whereas the resting plasma nitrite did not differ. No serious adverse events occurred.
Conclusions
L-arginine supplementation at 6 g/day for 8 weeks reduced fatigue severity relative to placebo and was well-tolerated; however, mean FSS scores remained above the enrollment threshold, indicating a reduction in, rather than resolution of, persistent fatigue.
Sources et attribution
Effects of Oral L-Arginine on Everyday Persistent Fatigue, Sleep, and Post-Exercise Lactate Recovery in Community-Dwelling Working-Age Adults: A Double-Blind, Placebo-Controlled Randomized Trial.
Kang EB, Hong SB, Yoon N, Lee N, Kim B.
Nutrients · 2026-10-14
DOI: 10.3390/nu18203375 ↗PubMed · 42942946 ↗Europe PMC · Licence indiquée: cc by ↗Abstract © the original authors, reproduced under the recorded open licence. Translations support reading; use the English record to check terminology and numerical results. Our methodological interpretation is separate from the authors’ conclusions.
Interprétation éditoriale MoveVitals · contenu éducatif · aucune évaluation clinique individuelle enregistrée
Sources vérifiées 2026-11-01
Guides pratiques
À lire ensemble
Exercise improved sleep-quality scores in adults 45 and older with sleep disorders
Pooling 23 randomized trials with 1,478 adults aged 45 to 77 who had sleep disorders, exercise improved Pittsburgh Sleep Quality Index scores (SMD 0.62, 95% CI 0.40–0.83), and aerobic exercise showed the largest effect in the network analysis (SMD 1.34, 95% CrI 0.86–1.82). Certainty was low to moderate, the outcomes were questionnaires, and the best weekly dose of about 539 MET-min/week is a model estimate, not a prescription.
Journal of Exercise Science & Fitness
Sleep regularity tracked mortality more closely than sleep duration in 60,977 UK adults
Among 60,977 UK Biobank adults who wore a wrist accelerometer for a week, the most regular fifth of sleepers had a fully adjusted all-cause mortality HR of 0.70 (95% CI 0.59–0.83) against the least regular fifth, over about 6.3 years and 1859 deaths. Regularity fitted the data better than sleep duration, but the study is observational and rests on one week of sleep data.
Sleep
Sleep extension cut daily energy intake by about 270 kcal in adults with overweight
In 80 adults with overweight who usually slept under 6.5 hours, two weeks of sleep-extension counselling added about 1.2 hours of sleep and lowered measured energy intake by 270.4 kcal/d versus control (95% CI −393.4 to −147.4). The trial was short, single-centre and in a narrow group, so it does not show lasting weight loss or any benefit for people who already sleep enough.
JAMA Internal Medicine
Six hours or less of sleep at 50 and 60 linked to higher dementia risk
In 7959 British civil servants followed for about 25 years, sleeping six hours or less at age 50 (HR 1.22, 95% CI 1.01–1.48) or age 60 (HR 1.37, 1.10–1.72) was linked to a higher dementia rate than sleeping seven hours, and persistent short sleep gave an HR of 1.30 (1.00–1.69). Sleep was mostly self-reported and the study is observational, so early brain disease or other factors may explain part of the link.
Nature Communications

